Literature DB >> 10944807

The role of CpG in DNA vaccines.

M J McCluskie1, R D Weeratna, H L Davis.   

Abstract

One of the most exciting developments in the field of vaccine research in recent years has been DNA vaccines, with which immune responses are induced subsequent to the in vivo expression of antigen from directly introduced plasmid DNA. Strong immune responses have been demonstrated in a number of animal models against many viral, bacterial and parasitic pathogens, and several human clinical trials have been undertaken. The strong and long-lasting antigen-specific humoral (antibodies) and cell-mediated (T help, other cytokine functions and cytotoxic T cells) immune responses induced by DNA vaccines appear to be due to the sustained in vivo expression of antigen, efficient antigen presentation and the presence of stimulatory CpG motifs. These features are desirable for the development of prophylactic vaccines against numerous infectious agents. Furthermore, the strong cellular responses are also very desirable for the development of therapeutic DNA vaccines to treat chronic viral infections or cancer. Efforts are now focusing on understanding the mechanisms for the induction of these immune responses, which in turn should aid in the optimization of DNA vaccines. This review will focus on the role of CpG motifs in DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944807     DOI: 10.1007/s002810000014

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  63 in total

1.  Genetic immunization is a simple method for eliciting an immune response.

Authors:  D C Tang; M DeVit; S A Johnston
Journal:  Nature       Date:  1992-03-12       Impact factor: 49.962

2.  Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice.

Authors:  D Broide; J Schwarze; H Tighe; T Gifford; M D Nguyen; S Malek; J Van Uden; E Martin-Orozco; E W Gelfand; E Raz
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

3.  Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine.

Authors:  S Sasaki; K Hamajima; J Fukushima; A Ihata; N Ishii; I Gorai; F Hirahara; H Mohri; K Okuda
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

4.  Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes.

Authors:  M J McCluskie; Y M Wen; Q Di; H L Davis
Journal:  Viral Immunol       Date:  1998       Impact factor: 2.257

5.  The effect of interferon-gamma on genetic immunization.

Authors:  Z Q Xiang; Z He; Y Wang; H C Ertl
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

6.  Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung.

Authors:  R K Scheule; J A St George; R G Bagley; J Marshall; J M Kaplan; G Y Akita; K X Wang; E R Lee; D J Harris; C Jiang; N S Yew; A E Smith; S H Cheng
Journal:  Hum Gene Ther       Date:  1997-04-10       Impact factor: 5.695

7.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

8.  Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.

Authors:  N J Caplen; E W Alton; P G Middleton; J R Dorin; B J Stevenson; X Gao; S R Durham; P K Jeffery; M E Hodson; C Coutelle
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  Myoblast transfer in Duchenne muscular dystrophy.

Authors:  G Karpati; D Ajdukovic; D Arnold; R B Gledhill; R Guttmann; P Holland; P A Koch; E Shoubridge; D Spence; M Vanasse
Journal:  Ann Neurol       Date:  1993-07       Impact factor: 10.422

10.  Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope.

Authors:  S Casares; K Inaba; T D Brumeanu; R M Steinman; C A Bona
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

View more
  7 in total

1.  Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells.

Authors:  Kristina Abel; Yichuan Wang; Linda Fritts; Eleonora Sanchez; Eugene Chung; Patricia Fitzgerald-Bocarsly; Arthur M Krieg; Christopher J Miller
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

2.  Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.

Authors:  Alexander H Dalpke; Stefan Zimmermann; Inka Albrecht; Klaus Heeg
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

Review 3.  ATF3 transcription factor and its emerging roles in immunity and cancer.

Authors:  Matthew R Thompson; Dakang Xu; Bryan R G Williams
Journal:  J Mol Med (Berl)       Date:  2009-08-25       Impact factor: 4.599

4.  Identification of two subpopulations of purified human blood B cells, CD27- CD23+ and CD27high CD80+, that strongly express cell surface Toll-like receptor 9 and secrete high levels of interleukin-6.

Authors:  Fabrice Cognasse; Hind Hamzeh-Cognasse; Sandrine Lafarge; Patricia Chavarin; Bruno Pozzetto; Yolande Richard; Olivier Garraud
Journal:  Immunology       Date:  2008-04-28       Impact factor: 7.397

Review 5.  T cell immunity in neonates.

Authors:  A M Garcia; S A Fadel; S Cao; M Sarzotti
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

6.  Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.

Authors:  Christiane L Schnabel; P Steinig; M Koy; H-J Schuberth; C Juhls; D Oswald; B Wittig; S Willenbrock; H Murua Escobar; C Pfarrer; B Wagner; P Jaehnig; A Moritz; K Feige; J-M V Cavalleri
Journal:  BMC Vet Res       Date:  2015-06-23       Impact factor: 2.741

7.  CpG DNA facilitate the inactivated transmissible gastroenteritis virus in enhancing the local and systemic immune response of pigs via oral administration.

Authors:  Jian Lin; Chongzhi Tu; Chunxiao Mou; Xiaojuan Chen; Qian Yang
Journal:  Vet Immunol Immunopathol       Date:  2016-02-20       Impact factor: 2.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.